NUROMAX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NUROMAX (NUROMAX).
Neuromuscular blocking agent; competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, preventing depolarization and muscle contraction.
| Metabolism | Hepatic (CYP450 enzymes, primarily CYP3A4); active metabolite (17-desacetylvecuronium) formed. |
| Excretion | Renal: 80-90% unchanged; biliary: 10-20% |
| Half-life | Terminal half-life: 1.5-2.5 hours; prolonged in renal impairment (up to 5 hours) and hepatic disease |
| Protein binding | ~30-40%; primarily albumin |
| Volume of Distribution | 0.2-0.3 L/kg (central compartment); total Vd ~0.3-0.4 L/kg, indicating limited extravascular distribution |
| Bioavailability | IV only; oral: negligible due to poor absorption and first-pass metabolism; not administered orally |
| Onset of Action | IV: 2-4 minutes (intubating dose 0.08-0.12 mg/kg); peak effect at 3-5 minutes |
| Duration of Action | IV: 25-40 minutes (initial intubating dose); longer with repeated doses due to accumulation; clinical duration: 30-60 minutes for neuromuscular block |
| Action Class | Vitamins |
| Brand Substitutes | Nurokind Injection, ME 12 Injection, Miol Forte 500mcg Injection, Mecolbin Injection, Meconerv Injection |
0.1 mg/kg IV bolus, then 0.015 mg/kg IV as needed for neuromuscular blockade.
| Dosage form | INJECTABLE |
| Renal impairment | GFR <30 mL/min: reduce maintenance infusion by 50% and monitor neuromuscular transmission. |
| Liver impairment | Child-Pugh class B or C: reduce initial dose by 50% and titrate to effect. |
| Pediatric use | Neonates and infants: 0.1 mg/kg IV initial dose, then 0.01–0.02 mg/kg as needed. Children >2 years: 0.1 mg/kg IV initial, then 0.015 mg/kg as needed. |
| Geriatric use | Initial dose 0.08 mg/kg IV; increased sensitivity to neuromuscular blockade, monitor with train-of-four. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NUROMAX (NUROMAX).
| Breastfeeding | No human data; M/P ratio unknown. Not recommended unless benefit outweighs risk. Advise breastfeeding cessation during therapy. |
| Teratogenic Risk | FDA Pregnancy Category C. In animal studies, doses 0.4 times the maximum human dose resulted in skeletal malformations. First trimester: potential for major congenital malformations based on animal data; second and third trimesters: risk of fetal skeletal abnormalities and reduced fetal weight. Use only if benefit outweighs risk. |
| Fetal Monitoring |
■ FDA Black Box Warning
Should be administered only by adequately trained individuals familiar with its actions, characteristics, and hazards. Facilities for intubation, artificial respiration, oxygen therapy, and reversal agents must be immediately available.
| Serious Effects |
Known hypersensitivity to vecuronium or other neuromuscular blocking agents
| Precautions | Risk of prolonged neuromuscular blockade; anaphylaxis; residual paralysis; careful monitoring of neuromuscular function; use in patients with myasthenia gravis, electrolyte disturbances, or altered drug metabolism. |
Loading safety data…
| Monitor maternal vital signs, respiratory function, and neuromuscular blockade. Fetal monitoring: heart rate and movement patterns. Consider ultrasound for skeletal development if used in second/third trimester. |
| Fertility Effects | In animal studies, reduced fertility and implantation rates at doses 0.4 times the maximum human dose. Human data lacking; potential for reversible impairment. |